The hottest new economic growth point of China's p

2022-08-08
  • Detail

New economic growth point of China's pharmaceutical packaging industry

the output value of China's pharmaceutical packaging industry has accounted for more than 10% of the total output value of the national packaging industry, which is higher than the proportion of the output value of the pharmaceutical industry in the total industrial output value of the country. Although there is a certain gap between the output value of the pharmaceutical packaging industry in developed countries accounting for 30% of the total output value of the pharmaceutical industry by exerting strong pressure on the metal blank to produce plastic deformation and fracture to process parts, However, this just shows that there is still a broad market space for tailor-made "new clothes" for drugs. According to the data of the American flexible packaging Association, the global pharmaceutical packaging market increased by 4.2% in 2003, and the output value reached US $11.2 billion. In the next five years, pharmaceutical packaging will become the second largest economic growth point of flexible packaging, and China will become the fastest growing region

according to the statistical data of SFDA Southern Institute of pharmaceutical economics, the development rate of China's pharmaceutical industry reached 22% in 2003. In the global economic warming environment, with the introduction of a series of policies and regulations in China's pharmaceutical industry, the pharmaceutical industry will continue to grow in 2004, with an expected increase of 25%

Caihong, Secretary General of China Pharmaceutical Packaging Association, said that the output value of China's pharmaceutical packaging industry has accounted for more than 10% of the national packaging industry output value, which is higher than the proportion of the pharmaceutical industry output value in the national total industrial output value. Although there is a certain gap with the developed countries' pharmaceutical packaging output value accounting for 30% of the total output value of the pharmaceutical industry, this shows that today, with the endless emergence of new drug dosage forms, there is still a broad market space for tailor-made "new clothes" for drugs

trend

as a commodity, the packaging of drugs, like other commodity packaging, can directly affect the sales of drugs. Therefore, major pharmaceutical companies in the world have always attached great importance to the packaging of drugs, and drug packaging has also achieved rapid development in recent years. According to the data of American flexible packaging Association, the global pharmaceutical packaging market increased by 4.2% in 2003, reaching an output value of 11.2 billion US dollars. In the next five years, China will become the region with the largest growth

based on this prospect, the pharmaceutical packaging industry will show a trend of good prospects and large development space in the next few years. How to seize this opportunity of development is a problem worthy of consideration for every pharmaceutical packaging enterprise. Ji Wei, director of Shanghai Pharmaceutical Packaging and testing institute, said that from the perspective of long-term development strategy, the first thing for enterprises is to improve their own R & D capacity for packaging, have independent products, constantly innovate new materials and products, and improve the grade of new materials

with the continuous progress of new materials, new technologies and new processes, drug packaging will show a trend of being more convenient, safe and more in line with environmental protection requirements. It is estimated that the sales of drug packaging materials will increase at the same time as the sales of drugs, and the growth of drug packaging sales may be greater than the growth of drug sales, because pharmaceutical companies are willing to buy packaging that is higher price, safer, damage proof, child proof, convenient for the elderly and can protect privacy

analyze the "hidden worries"

China's pharmaceutical packaging industry has been an extensive growth with high efficiency, low efficiency and high consumption. The packaging quality of most drugs is low, and nearly 70% of drug packaging does not meet international standards. Caihong, Secretary General of China Pharmaceutical Packaging Association, believes that this gap is mainly reflected in the relevant regulations on pharmaceutical packaging, the overall production technology level of drug packaging materials, the management and anti-counterfeiting of labels, and the safety and environmental protection of drug packaging materials. Before 2000, the only law related to drugs was the drug administration law, in which the regulations and management systems related to drug packaging and labeling were relatively backward, and serious adverse reactions occurred from time to time due to unclear labels and instructions or incomplete information. The case of carbamazepine in 1995 is a typical example. The packaging of most drugs in China is very simple, some of which are only pasted with anti-counterfeiting labels on the outer packaging box, and advanced technology is not used in the manufacturing and printing of the box, which objectively provides convenience for counterfeiters. At present, there are seven categories of technologies that can be used for pharmaceutical anti-counterfeiting, including digital anti-counterfeiting, ink anti-counterfeiting, paper anti-counterfeiting, special printing anti-counterfeiting, nuclear track anti-counterfeiting, biological anti-counterfeiting, etc., but some technologies have not been adopted by Chinese pharmaceutical enterprises, such as DNA anti-counterfeiting technology often used by pharmaceutical enterprises in developed countries in Europe and the United States. Objectively speaking, Chinese pharmaceutical enterprises are still relatively backward in anti-counterfeiting packaging technology. Although they have a certain understanding of the importance of packaging anti-counterfeiting, they still invest less in technology. Pharmaceutical anti-counterfeit packaging is urgent. A survey from the State Food and Drug Administration shows that the overall technical level of China's pharmaceutical packaging materials industry is not high, the grade is low, far behind developed countries, and the quality of packaging materials and the contribution rate of packaging to the pharmaceutical industry are low

in developed countries, pharmaceutical packaging accounts for 30% of the value of drugs, while in China, it is only 10%. At the same time, medicine is a special industry. The primary function of pharmaceutical packaging materials is to ensure the safety of drugs within the period of validity, and the proportion of usage in the consumption of packaging materials in the country is very low. As long as we pay attention to recycling, it will not cause adverse effects on the environment. Nevertheless, the development of environmentally friendly plastic packaging materials is still the direction of drug packaging development

in the past two years, the large-scale production of pharmaceutical enterprises has become more and more obvious. One development trend of modern pharmaceutical enterprises is that large pharmaceutical factories have their own packaging enterprises. These large-scale pharmaceutical enterprises are not much different from foreign enterprises in hardware, but the software environment is not satisfactory. The reason is that Mr. Chen Linxiang, Secretary General of the packaging and Printing Committee of China Packaging Technology Association, believes that in addition to the relatively backward policies and technical standards, as well as the overall low level and backward technology of domestic pharmaceutical production enterprises, there are also drawbacks in the pharmaceutical circulation system. Most drugs are sold in hospital pharmacies, and a small part of them are sold in pharmacies, which limits the fracture life of other tapes in addition to this kind of tooth loss life. Drugs participate in direct competition, thus restricting the development of pharmaceutical packaging. In addition, the current bidding system has seriously dampened the enthusiasm of pharmaceutical manufacturers, and enterprises can not make great efforts in the packaging link, maintaining the "old face" for a long time

get out of the "blind spot"

with the improvement of domestic people's living standards and the introduction of OTC drug policies, drug packaging has gradually become an important factor in market competition. Wang Weiping of Beijing Sitai Printing Co., Ltd. said that pharmaceutical enterprises with foreign capital background generally attach great importance to drug packaging, because they believe that packaging is an important part of product image, and the internal and external appearance of products should be consistent. According to her introduction, at present, most domestic pharmaceutical enterprises choose relatively cheap white paper as the packaging material of medicine boxes, mainly for the purpose of reducing costs. Domestic enterprises are generally unwilling to spend more money, and the common practice is to save as much as possible. In fact, these enterprises have several conceptual misunderstandings. For example, when using high-grade paperboard to replace the lower price 300 grams of paperboard, the same number of grams is not required, and usually only 250 grams is required. However, when domestic enterprises switch to high-grade whiteboard, they still choose 300 grams of paperboard, resulting in unnecessary waste; There are also enterprises that believe that some engineering components whose drug prices are controlled by fatigue failure can only choose high-grade packaging cardboard. For low-cost drugs, of course, choose cheap cardboard; Some enterprises require film covering on the printed paperboard because the low-cost paperboard is not crisp enough, which not only increases the cost, but also is not environmentally friendly. Wang Weiping believes that the main reason for enterprises to enter these misunderstandings is that domestic enterprises do not have a strong sense of packaging economy and do not pay enough attention to it

the packaging board of Beijing Novartis pharmaceutical company is the product of a European company. Talking about the reasons, the head of the company's Logistics Department said that we first attach importance to the reputation of suppliers and product quality. Now the products used are from suppliers from Novartis' European headquarters, which comply with international norms in terms of safety, environmental protection, health control and so on. The second is the price factor. Domestic paperboard suppliers have price advantages, but they still need additional certification fees to obtain recognition

Zhang Heyong, President of China Pharmaceutical Packaging Association, believes that the awareness of pharmaceutical packaging should not become a "blind spot" in the packaging industry. At present, the domestic pharmaceutical packaging industry shows the following characteristics: most of the Western medicines produced by joint ventures have relatively reasonable packaging design, which meets the requirements of pharmaceutical administration; Some domestic enterprises have been making drug packaging for decades, with rough surface, especially the problem of Chinese patent medicine. It is worth mentioning that flexible packaging has become the biggest problem in the packaging of tablet drugs, especially sugar coated tablets. Tablets often strip and crack due to mutual friction. In addition, some manufacturers blindly increase the size of the packaging box in order to enhance the visual impact, which is large outside and small inside. It is not only flashy, but also not conducive to reducing friction and damage in drug transportation. It also increases the packaging cost and increases the burden on consumers. The quality of drug packaging should be standardized and managed as drug quality, and listed in GMP certification

"new clothes" awareness

packaging is the carrier of information. Now the new concept that is gradually being recognized by industry insiders is: don't blindly save money on the packaging box. If you choose a better cardboard, you don't have to spend more money, and you may also find a small new economic growth point. In this regard, Caihong believes that at present, many domestic pharmaceutical packaging is not only backward in design, but also mostly uses gray bottom white board paper with recycled pulp as raw material, which is neither beautiful nor hygienic. Some toxic substances in recycled pulp still exist in the packaging board. The packaging size and design of some enterprises' products are unreasonable, and some color designs are not suitable for printing, especially the enterprises' lack of attention to the cartoning rate of paperboard, which have caused potential waste of funds. In this case, if the enterprise wants to maintain a low packaging cost, it is bound to further reduce the grade of the packaging box

some insiders believe that today, when product homogenization is becoming more and more obvious, product packaging is becoming an effective way to distinguish its own products from other products. According to Cai Hong, in recent years, with the rapid development of information technology and pharmaceutical packaging industry, the international paper industry is also constantly penetrating into the packaging field, and according to the characteristics of different industries and the special requirements of different products for packaging, we have developed products that can meet the user's anti-counterfeiting, personalized design, easy to print, and have a crisp, economic and reasonable appearance. With the reform of the medical system and the implementation of drug classification management, the proportion of patients choosing drugs by themselves will be greatly increased, and the beautiful packaging can have an impact on the vision of consumers, produce a sense of trust in the quality of drugs, and thus improve the desire to buy. Therefore, pharmaceutical enterprises should pay enough attention to the appearance, design and quality of packaging. Especially for OTC drugs, packaging will be an important means of market competition

the way of dressing up

internationally, the customers of the pharmaceutical industry in the past were mainly doctors and pharmacists. Today, with the gradual increase of the trend of self purchase by consumers, the pharmaceutical industry is also booming, and the passenger routes are becoming wider and wider

the new development trend of the international pharmaceutical packaging market is that white packaging technology is widely used, mechanical technology packaging has become a new upstart, and the safety of pharmaceutical packaging has been paid more and more attention. In the midst of this trend, how can Chinese pharmaceutical companies tailor drugs

Copyright © 2011 JIN SHI